Current status of zika virus vaccines: Successes and challenges

Aryamav Pattnaik, Bikash R. Sahoo, Asit K. Pattnaik

Research output: Contribution to journalReview articlepeer-review

72 Scopus citations


The recently emerged Zika virus (ZIKV) spread to the Americas, causing a spectrum of congenital diseases including microcephaly in newborn and Guillain-Barré syndrome (GBS) in adults. The unprecedented nature of the epidemic and serious diseases associated with the viral infections prompted the global research community to understand the immunopathogenic mechanisms of the virus and rapidly develop safe and efficacious vaccines. This has led to a number of ZIKV vaccine candidates that have shown significant promise in human clinical trials. These candidates include nucleic acid vaccines, inactivated vaccines, viral-vectored vaccines, and attenuated vaccines. Additionally, a number of vaccine candidates have been shown to protect animals in preclinical studies. However, as the epidemic has waned in the last three years, further development of the most promising vaccine candidates faces challenges in clinical efficacy trials, which is needed before a vaccine is brought to licensure. It is important that a coalition of government funding agencies and private sector companies is established to move forward with a safe and effective vaccine ready for deployment when the next ZIKV epidemic occurs.

Original languageEnglish (US)
Article number266
Issue number2
StatePublished - Jun 2020


  • ADE
  • Correlates of protection
  • Immunoinformatics
  • Vaccine platforms and vaccine candidates
  • Zika virus

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Drug Discovery
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Current status of zika virus vaccines: Successes and challenges'. Together they form a unique fingerprint.

Cite this